Publication:
Identification of Predictive Biomarkers of Response to HSP90 Inhibitors in Lung Adenocarcinoma.

dc.contributor.authorMarrugal, Ángela
dc.contributor.authorFerrer, Irene
dc.contributor.authorGómez-Sánchez, David
dc.contributor.authorQuintanal-Villalonga, Álvaro
dc.contributor.authorPastor, María Dolores
dc.contributor.authorOjeda, Laura
dc.contributor.authorPaz-Ares, Luis
dc.contributor.authorMolina-Pinelo, Sonia
dc.date.accessioned2023-02-09T10:48:47Z
dc.date.available2023-02-09T10:48:47Z
dc.date.issued2021-03-03
dc.description.abstractHeat shock protein 90 (HSP90) plays an essential role in lung adenocarcinoma, acting as a key chaperone involved in the correct functioning of numerous highly relevant protein drivers of this disease. To this end, HSP90 inhibitors have emerged as promising therapeutic strategies, even though responses to them have been limited to date. Given the need to maximize treatment efficacy, the objective of this study was to use isobaric tags for relative and absolute quantitation (iTRAQ)-based proteomic techniques to identify proteins in human lung adenocarcinoma cell lines whose basal abundances were correlated with response to HSP90 inhibitors (geldanamycin and radicicol derivatives). From the protein profiles identified according to response, the relationship between lactate dehydrogenase B (LDHB) and DNA topoisomerase 1 (TOP1) with respect to sensitivity and resistance, respectively, to geldanamycin derivatives is noteworthy. Likewise, rhotekin (RTKN) and decaprenyl diphosphate synthase subunit 2 (PDSS2) were correlated with sensitivity and resistance to radicicol derivatives. We also identified a relationship between resistance to HSP90 inhibition and the p53 pathway by glucose deprivation. In contrast, arginine biosynthesis was correlated with sensitivity to HSP90 inhibitors. Further study of these outcomes could enable the development of strategies to improve the clinical efficacy of HSP90 inhibition in patients with lung adenocarcinoma.
dc.identifier.doi10.3390/ijms22052538
dc.identifier.essn1422-0067
dc.identifier.pmcPMC7962034
dc.identifier.pmid33802597
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962034/pdf
dc.identifier.unpaywallURLhttps://www.mdpi.com/1422-0067/22/5/2538/pdf?version=1614863993
dc.identifier.urihttp://hdl.handle.net/10668/17468
dc.issue.number5
dc.journal.titleInternational journal of molecular sciences
dc.journal.titleabbreviationInt J Mol Sci
dc.language.isoen
dc.organizationInstituto de Biomedicina de Sevilla-IBIS
dc.organizationHospital Universitario Virgen del Rocío
dc.pubmedtypeJournal Article
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectHSP90 inhibitors
dc.subjectlung adenocarcinoma
dc.subjectprotein biomarkers predictive of response
dc.subject.meshA549 Cells
dc.subject.meshAdenocarcinoma of Lung
dc.subject.meshAntineoplastic Agents
dc.subject.meshBenzoquinones
dc.subject.meshBiomarkers, Tumor
dc.subject.meshCell Line, Tumor
dc.subject.meshHSP90 Heat-Shock Proteins
dc.subject.meshHumans
dc.subject.meshLactams, Macrocyclic
dc.subject.meshLung Neoplasms
dc.subject.meshMolecular Chaperones
dc.subject.meshProteomics
dc.titleIdentification of Predictive Biomarkers of Response to HSP90 Inhibitors in Lung Adenocarcinoma.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number22
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC7962034.pdf
Size:
8.19 MB
Format:
Adobe Portable Document Format